Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
289.6 INR | +3.37% | +8.38% | +16.00% |
Apr. 18 | India's Biocon developing its own version of Wegovy, clinical trial likely next year | RE |
Apr. 18 | Biocon Signs Licensing and Supply Pact with Biomm to Commercialize Generic Ozempic in Brazil | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.00% | 4.02B | |
-0.35% | 105B | |
+4.00% | 97.5B | |
+2.45% | 22.19B | |
-15.96% | 21.33B | |
-7.63% | 18.68B | |
-41.41% | 16.6B | |
-19.03% | 14.52B | |
+7.82% | 14.09B | |
+22.53% | 10.99B |
- Stock Market
- Equities
- BIOCON Stock
- News Biocon Limited
- Biocon : Arm Faces US FDA Approval Delay for Bevacizumab